Delaware
|
94-3023969
|
|
(State
or Other Jurisdiction of
|
(I.R.S.
Employer Identification No.)
|
|
Incorporation)
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
Release, dated July 28, 2010, regarding the financial results of PDL
BioPharma, Inc. for the second quarter ended June 30,
2010
|
|
99.2
|
Information Sheet, dated July 28, 2010 |
PDL
BIOPHARMA, INC.
|
|||
(Company)
|
|||
|
By:
|
/s/ Christine R. Larson | |
Christine R. Larson | |||
Vice President and Chief Financial Officer | |||
Exhibit
No.
|
Description
|
|
99.1
|
Press
Release, dated July 28, 2010, regarding the financial results of PDL
BioPharma, Inc. for the second quarter ended June 30,
2010
|
|
99.2
|
Information Sheet, dated July 28, 2010 |